Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
Veracyte (VCYT) Stock Price & Analysis
427 Followers
VCYT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.61 - $30.52
Previous Close$23.4
Volume628.70K
Average Volume (3M)730.25K
Market Cap
$1.79B
Enterprise Value$1.59B
Total Cash (Recent Filing)$216.45M
Total Debt (Recent Filing)$12.63M
Price to Earnings (P/E)-25.0
Beta1.93
Next Earnings
Jul 30, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding76,448,070
10 Day Avg. Volume834,680
30 Day Avg. Volume730,250
Standard Deviation0.16
R-Squared0.30
Alpha-0.00814
Financial Highlights & Ratios
Price to Book (P/B)6.97
Price to Sales (P/S)18.22
Price to Cash Flow (P/CF)28.30
P/FCF Ratio28.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.39
Enterprise Value/Gross Profit4.50
Enterprise Value/Ebitda-56.31
Forecast
1Y Price Target
$29.40Price Target Upside28.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Veracyte News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceVCYT's revenue exceeded expectations, with strong performance driven by key products Decipher and Afirma.
Guidance UpdateVCYT raised its financial guidance for the year, indicating confidence in continued revenue growth and business performance.
Market OpportunityVCYT's core business of Decipher and Afirma tests is growing, addressing a market estimated at $35 billion, showing the company's significant market opportunity.
Bears Say
EarningsEPS missed consensus expectations.
Financial PerformanceProduct revenue declined due to supplier issues.
Revenue GrowthRevenue growth slowed significantly.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $18.61 and its highest was $30.52 in the past 12 months.
What is Veracyte’s market cap?
Currently, no data Available
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Jul 30, 2024 which is in 73 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on May 07, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.159 by $0.139.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is -$0.04.
How many shares outstanding does Veracyte have?
Veracyte has 76,448,070 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.159. Following the earnings report the stock price went down -4.327%.
Which hedge fund is a major shareholder of Veracyte?
Among the largest hedge funds holding Veracyte’s share is ARK Investment Management LLC. It holds Veracyte’s shares valued at 211M.
---
Veracyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.40 (28.50% Upside)
$29.40 (28.50% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 99.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $243.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.80%
12-Months-Change
Fundamentals
Return on Equity
-6.20%
Trailing 12-Months
Asset Growth
3.71%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
---
VCYT Company Deck
---
VCYT Earnings Call
Q1 2024
0:00 / 0:00
---
VCYT Stock 12 Month Forecast
Average Price Target
$29.40
▲(28.50% Upside)
Technical Analysis
Best Analysts Covering VCYT
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+44.75%
reiterated a buy rating 10 days ago
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +44.75% per trade.
---